Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.70 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3210628 | 0.98 | ALDH1A1 (0.73) | SIGMAR1ALDH1A1KDM4ECYP2A13POLB | |
| Hydrochloric Acid SCHEMBL11467058 | 0.98 | SIGMAR1 (0.70) | SIGMAR1ALDH1A1KDM4ECYP2A13POLB | |
| SCHEMBL5738303 | 0.98 | ALDH1A1 (0.73) | SIGMAR1ALDH1A1KDM4ECYP2A13POLB | |
| Hydrochloric Acid SCHEMBL16825204 | 0.96 | ALDH1A1 (0.71) | SIGMAR1ALDH1A1KDM4ECYP2A13POLB | |
| SCHEMBL23851311 | 0.96 | SIGMAR1 (0.72) | SIGMAR1ALDH1A1KDM4ECYP2A13POLB | |
| SCHEMBL11360607 | 0.91 | SIGMAR1 (0.85) | SIGMAR1ALDH1A1KDM4ECYP2A13PLA2G1B | |
| SCHEMBL2095997 | 0.84 | SIGMAR1 (0.58) | SIGMAR1ALDH1A1KDM4ECYP2A13POLB | |
| SCHEMBL2266141 | 0.84 | CXCR4 (0.58) | SIGMAR1ALDH1A1KDM4ECYP2A13POLB | |
| SCHEMBL12993260 | 0.84 | KDM4E (0.68) | SIGMAR1ALDH1A1KDM4ECYP2A13POLB | |
| SCHEMBL11196594 | 0.84 | ALDH1A1 (0.69) | SIGMAR1ALDH1A1KDM4EPOLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4221805-A | N-(2-CHLOROBENZYL)PYRROLIDINE | QUADRO GIUSEPPE | 1980-09-09 | — | — | US | claimed |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-04-12 | — | — | US | disclosed |
| EP-3193604-B1 | SUBSTITUTED N-(PYRROLIDIN-3-YL)ISOXAZOLE-3-CARBOXAMIDE COMPOUNDS | EPIZYME INC (US) | 2021-06-16 | — | — | EP | disclosed |
| WO-2017201468-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | WO | disclosed |
| US-20140088069-A1 | NOVEL ANTIBACTERIAL COMBINATION THERAPY | MCMASTER UNIVERSITY (CA) | 2014-03-27 | — | — | US | disclosed |
| US-20140088069-A1 | NOVEL ANTIBACTERIAL COMBINATION THERAPY | MCMASTER UNIVERSITY (CA) | 2014-03-27 | — | — | US | disclosed |
| US-20140088069-A1 | NOVEL ANTIBACTERIAL COMBINATION THERAPY | MCMASTER UNIVERSITY (CA) | 2014-03-27 | — | — | US | disclosed |
| EP-2364314-B1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES INC (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012162814-A1 | NOVEL ANTIBACTERIAL COMBINATION THERAPY | MCMASTER UNIVERSITY (CA) | 2012-12-06 | — | — | WO | disclosed |
| EP-0581456-A1 | Use of phenylpyrrolidines for the manufacture of a medicament for the treatment of neurodegenerative diseases | R.J. REYNOLDS TOBACCO COMPANY (US) | 1994-02-02 | — | — | EP | disclosed |
| US-5248690-A | Nervous system disorders such as Parkinson*s disease | R. J. REYNOLDS TOBACCO COMPANY (US) | 1993-09-28 | — | — | US | disclosed |
| US-4221805-A | N-(2-CHLOROBENZYL)PYRROLIDINE | QUADRO GIUSEPPE | 1980-09-09 | — | — | US | disclosed |
| US-4221805-A | N-(2-CHLOROBENZYL)PYRROLIDINE | QUADRO GIUSEPPE | 1980-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | SIGMAR1 3293/4885ALDH1A1 2797/4885KDM4E 1252/4885 |
| US-20140088069-A1 | NOVEL ANTIBACTERIAL COMBINATION THERAPY | NCBP2, TPX2, GTPBP4 | SIGMAR1 1220/4885ALDH1A1 4803/4885KDM4E 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.